Author
1. Chopra HK
2. Pancholia AK
3. Malhi Harshveer Singh
ISBN
9789351521099
DOI
10.5005/jp/books/18376_109
Edition
1/e
Publishing Year
2021
Pages
13
Author Affiliations
1.
Moolchand Medcity Hospital, New Delhi, India,
Medanta Moolchand Heart Institute, Moolchand Medcity, New Delhi, India,
Medanta Moolchand Heart Institute, Moolchand Medcity; World Wellness Foundation, WHA; AHA,
Medanta Moolchand Heart Institute; Moolchand Medcity; World Wellness Foundation, WHA; CSI & IAE; IHJ, JIAE,
Medanta Moolchand Heart Institute; Moolchand Medcity; World Wellness Foundation, WHA,
Medanta Moolchand Heart Institute, New Delhi, India; CME, Moolchand Medcity, World Wellness, Foundation and WHA; AHA; CSI and IAE; IHJ and JIAE,
IAE-2017, CSI-2015; World Wellness Foundation, Country Head, American Heart Association; Medanta Moolchand Heart Institute; Health Committee, SCOPE, Tata Sky FAM Health, New Delhi, India,
IAE- 2017, CSI -2015; World Wellness Foundation; American Heart Association; Moolchand Medcity; Physician Governing Body, CME, COP Moolchand Medcity, New Delhi, India,
IAE- 2017, CSI -2015; World Wellness Foundation; Physician Governing Body, CME, COP Moolchand Medcity, New Delhi, India
2.
Gokuldas Heart Center, Indore, Madhya Pradesh, India,
Arihant Hospital and RC, Indore, Madhya Pradesh, India,
Arihant Hospital, Indore, Madhya Pradesh, India,
Arihant Hospital and Gokuldas Heart Center, Indore, Madhya Pradesh, India,
Cardiology and Research Centre, Arihant Hospital, Indore, MP, India; National CSI,
Arihant Hospital and RC Gokuldas Heart Hospital, Indore, Madhya Pradesh, India,
Arihant Hospital and Research Center, Indore, Madhya Pradesh, India,
Arihant Hospital and Research Centre, Indore, Madhya Pradesh, India
3.
Allergopharma, Merck Specialities Private Limited, Mumbai, Maharashtra, India,
Biopharma l Medical Affairs, Merck Specialities Private Limited, Mumbai, Maharashtra, India,
Medical Affairs CM Care, Mumbai, Maharashtra, India
Chapter keywords
Bisoprolol,
hypertension,
β-blocker,
blood pressure,
BP,
coronary artery disease,
CAD,
pharmacology,
heart rate,
HR,
pharmacokinetic profile,
pharmacodynamic effect,
clinical evidence
